Evidence map›Paper›PMID 28138429›Full record

ArticleNeuroImage. Clinical2017

Evaluation of early-phase [

Sonja Daerr, Matthias Brendel, Christian Zach, Erik Mille, Dorothee Schilling, Mathias Johannes Zacherl, Katharina Bürger, Adrian Danek, Oliver Pogarell, Andreas Schildan and 5 more

Abstract read
In one paragraph

Article in NeuroImage. Clinical, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed.

  1. Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Trial
  2. Article
  3. Assessment of early-phase [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Evaluation of early-phaseJournal of Alzheimer's disease : JAD · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Early-phaseEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
  13. Article
  14. Assessment of [European journal of nuclear medicine and molecular imaging · 2024
    Article
  15. Early-Frame [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  16. Review
  17. Feasibility evaluation of middle-phaseQuantitative imaging in medicine and surgery · 2023
    Article
  18. Generation of ConventionalMedicina (Kaunas, Lithuania) · 2023
    Article
  19. Assessment of perfusion deficit with early phases of [European journal of nuclear medicine and molecular imaging · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sonja DaerrDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany.
Matthias BrendelDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany.
Christian ZachDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany.
Erik MilleDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany.
Dorothee SchillingDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany.
Mathias Johannes ZacherlDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany.
Katharina BürgerISD, Ludwig-Maximilians-Universität München, München, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Adrian DanekDept. of Neurology, Ludwig-Maximilians-Universität München, München, Germany.
Oliver PogarellDept. of Psychiatry, Ludwig-Maximilians-Universität München, München, Germany.
Andreas SchildanDept. of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Marianne PattDept. of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Henryk BarthelDept. of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Osama SabriDept. of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Peter BartensteinDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany; SyNergy, Ludwig-Maximilians-Universität München, München, Germany.
Axel RomingerDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany; SyNergy, Ludwig-Maximilians-Universität München, München, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn recent years several [

methodsAll subjects were recruited with clinical suspicion of dementia due to neurodegenerative disease. FDG PET was undertaken by conventional methods, and amyloid PET was performed with FBB, with early recordings for the initial 10 min (early-phase FBB), and late recordings at 90-110 min p.i. (late-phase FBB). Regional SUVR with cerebellar and global mean normalization were calculated for early-phase FBB and FDG PET. Pearson correlation coefficients between FDG and early-phase FBB were calculated for predefined cortical brain regions. Furthermore, a visual interpretation of disease pattern using 3-dimensional stereotactic surface projections (3D-SSP) was performed, with assessment of intra-reader agreement.

resultsAmong a total of 33 patients (mean age 67.5 ± 11.0 years) included in the study, 18 were visually rated amyloid-positive, and 15 amyloid-negative based on late-phase FBB scans. Correlation coefficients for early-phase FBB vs. FDG scans displayed excellent agreement in all target brain regions for global mean normalization. Cerebellar normalization gave strong, but significantly lower correlations. 3D representations of early-phase FBB visually resembled the corresponding FDG PET images, irrespective of the amyloid-status of the late FBB scans.

conclusionsEarly-phase FBB acquisitions correlate on a relative quantitative and visual level with FDG PET scans, irrespective of the amyloid plaque density assessed in late FBB imaging. Thus, early-phase FBB uptake depicts a metabolism-like image, suggesting it as a valid surrogate marker for synaptic dysfunction, which could ultimately circumvent the need for additional FDG PET investigation in diagnosis of dementia.

Indexed as

Positron-Emission TomographyAgedAmyloidogenic ProteinsAniline CompoundsDementiaFemaleHumansImaging, Three-DimensionalMaleMiddle AgedNeurodegenerative DiseasesStatistics as TopicStereotaxic TechniquesStilbenesTime Factors4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbeneAmyloidogenic ProteinsAniline CompoundsStilbenes[18F]-florbetaben PET3D-SSP, 3-dimensional stereotactic surface projectionsAD, Alzheimer's diseaseAlzheimer's diseaseCBF, cerebral blood flowCBL, cerebellumCN, cognitively normalFBB, [18F]florbetabenFDG, [18F]-fluorodeoxyglucoseFDG PetFTLD, frontotemporal lobar degenerationGLM, global meanL, leftMCI, mild cognitive impairmentMetabolismMNI, Montreal Neurological InstitutePCC, posterior cingulate cortexPerfusionPET, Positron emission tomographyp.i., post injectionR, rightSPECT, single photon emission computed tomographyß-amyloidSUVR, standardized uptake value ratioVOI, volume of interest

Identifiers

PMID28138429
PMCPMC5257027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.